Latest Sales Growth News

Generation Development Group reports a transformative FY25 with record Investment Bond sales and successful integration of Evidentia and Lonsec managed accounts, setting the stage for strong growth in FY26.

AnteoTech has signed a binding Term Sheet with US-based Black Diamond Structures to jointly develop and commercialise an advanced battery additive combining their proprietary technologies, targeting improved lithium-ion battery anodes with higher silicon content.

Immuron Limited reports a robust 49% increase in FY25 global sales of its immune supplement Travelan, driven by strong growth in Australia and North America. The company plans to accelerate its North American market presence in FY26.

ImpediMed has doubled its US unit sales in Q4 FY25, achieving a record total contract value and securing an additional $5 million tranche under its growth capital facility.

Meridian Energy’s June 2025 report reveals hydro storage levels exceeding historical averages and a notable rise in retail electricity sales, despite lower generation prices. The company also signals the end of its smelter demand response agreement.

Biome Australia Limited has reported a 69% increase in international sales revenue for FY25, reaching $1.5 million, driven by new strategic distribution agreements across Ireland, New Zealand, and Canada.

MyEco Group Ltd reported an 8.6% rise in FY25 sales driven by strong growth in its global MyEco® product line and new UK retail partnerships, while navigating challenges in resin markets and US tariffs.

Orthocell has achieved a significant milestone by recording its first US sales revenue for Remplir™, its flagship nerve repair product, shortly after FDA clearance and initial surgical use.

Biome Australia Limited has confirmed its record FY25 sales revenue of approximately $18.4 million, marking a 41% increase year-on-year, while affirming full compliance with ASX continuous disclosure rules.

Nova Eye Medical has reported a record A$28.8 million in revenues for FY25, driven by strong US sales and sustained growth of its flagship iTrack™ Advance device.

Botanix Pharmaceuticals reports robust early sales and expanding prescriber engagement for Sofdra™, its FDA-approved topical gel for excessive underarm sweating, signaling promising growth ahead.

RPMGlobal reports a strong 30.9% rise in software sales for FY2025, driven by subscription growth, with recurring revenue and backlog reaching new highs.